Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer - Wikidata - awgldk - TriplyDB

Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer

Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer

http://www.wikidata.org/entity/Q39118597

about

Regulation of ERBB3/HER3 signaling in cancer Current and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptors EGFR-TKI resistance in NSCLC patients: mechanisms and strategies Molecular pathways and therapeutic targets in lung cancer Strategy to enhance the therapeutic effect of doxorubicin in human hepatocellular carcinoma by selenocystine, a synergistic agent that regulates the ROS-mediated signaling.ERBB3 knockdown induces cell cycle arrest and activation of Bak and Bax-dependent apoptosis in colon cancer cells.CUL4A overexpression enhances lung tumor growth and sensitizes lung cancer cells to erlotinib via transcriptional regulation of EGFR.Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors.Potential therapeutic benefit of combining gefitinib and tamoxifen for treating advanced lung adenocarcinoma.Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2 The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer MLH1 V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients with EGFR L858R-positive lung adenocarcinoma Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth.Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression.ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology.TetraMabs: simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populations.Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ.Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib.MicroRNAs in melanoma development and resistance to target therapy.Clinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients.The natural compound fucoidan from New Zealand Undaria pinnatifida synergizes with the ERBB inhibitor lapatinib enhancing melanoma growth inhibition

P2860

Q27024334-23E5C1C9-40B5-4191-A2B6-F3C273E32106 Q28086768-BCD4B6BE-15E7-43CB-8BC8-0840A45B5947 Q28394310-89FB9A2C-913A-46B0-A8AA-0D734CD453EF Q33688872-48D1D807-126E-4F92-9AE6-3EB7F7D33094 Q33757127-90AC8F8E-15C9-4E01-A4B2-EF51A93CB498 Q34104165-B20D4D13-0AED-4201-9FD0-B27D0B65C803 Q34581688-B24931D5-0FE5-48A9-AD94-4020985F6364 Q34704781-4E53F692-52C8-4A28-9328-09E6181A3250 Q35062108-AD87B3B1-2324-4522-B5AE-5CA00EE838EC Q35273305-0279FDDE-93B6-4674-8EF4-64A51884EF93 Q35568803-7BF92724-97E3-4C85-B3DD-D2131CE044FC Q35742383-929027DE-9D0C-4ADC-9D36-38C3F677F320 Q35781614-E2F3ADC0-BE70-420D-92A1-338817BFEF86 Q36437261-4A818589-220A-4C62-B0C9-B6E12FDDD427 Q36634788-2076C090-AE32-42BD-AEAD-3FE0A4959EAF Q37190106-09C1795F-95D9-49A6-9BFD-B3D8B9B334AE Q38729111-1395DBF1-B712-4E10-80B1-7C5BEA4CDB53 Q38748906-55464E71-FADC-4188-BC49-47892ED9415E Q38860987-BC8BE883-3FD8-447D-A1FF-F4EB1BA5B4C0 Q38876644-531F26A8-048F-4B93-96BD-A842BCE4C1FD Q39101272-747B7B16-CC7E-4AF6-BCEB-C9605B6EF8C1 Q42279529-7E0F2CC0-6513-49E3-B8B7-0F542C23BAC4 Q42291455-6887E070-8B50-41CE-8D28-53B3F7F3427C

P2860

Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer

http://www.wikidata.org/entity/Q39118597

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Combination therapy with anti- ...... its non-small cell lung cancer

@en

Combination therapy with anti- ...... ts non-small cell lung cancer.

@nl

type

label

Combination therapy with anti- ...... its non-small cell lung cancer

@en

Combination therapy with anti- ...... ts non-small cell lung cancer.

@nl

prefLabel

Combination therapy with anti- ...... its non-small cell lung cancer

@en

Combination therapy with anti- ...... ts non-small cell lung cancer.

@nl

P1433

Q39118597-7A4A8580-0BCE-49A4-91D1-C5A799575E53

P1476

Q39118597-45204D96-7D51-41C1-9E8F-D83B9372FC53

P2093

Q39118597-1119E928-0D7A-424E-B46F-E36AAF443579

Q39118597-1DE5E892-FE7C-4EFB-8B0F-A60EE8ABA0B0

Q39118597-213485C7-7402-4C1E-92F0-94477C840E5B

Q39118597-4C7E1AB3-862E-4F14-ADBF-B480898E61FB

Q39118597-6114B76C-D450-4E9A-8C0C-C563F70DA939

Q39118597-6A50F8EC-9148-40A7-87A9-64F89423BCFF

Q39118597-77D27B17-634E-44C7-A78D-35650BC4450D

Q39118597-7C8ACB2A-5105-4FC1-9BDA-E450D5A6DF16

Q39118597-99A390D4-6BE4-427A-AE96-96C0F0AA11A7

Q39118597-DA43C2B0-43BF-4D74-B3D1-305CCAF76AB6

P2860

Q39118597-04A2B795-2594-4E69-BDA0-3841A320612B

Q39118597-22646883-8F76-47ED-B074-DB82A817BED2

Q39118597-25E430C9-62C4-4879-AF55-7590D24BA989

Q39118597-2A74E143-C17C-4422-8058-030C565F2F7D

Q39118597-3927D2DE-9A97-4A7A-A63E-E160A512952A

Q39118597-3A16A6E4-D9C5-4F32-A89B-CF5E53D5C9D8

Q39118597-3B61C06E-A015-46CE-B8DA-B9C3FB7A2F7E

Q39118597-405B1E5F-B3D3-4C37-9782-A47CB6223EBC

Q39118597-46AFABC4-62A5-4D43-9DD1-44D4AB8E89D5

Q39118597-49AD5465-1619-420F-B35A-4E96C2BEDA7C

P304

Q39118597-319E4CCE-734F-4C3D-9622-0BAB48B7A23D

P31

Q39118597-46513E43-A268-4E54-8AA0-C8F1A27D2861

P356

Q39118597-CC34CC06-B04D-425F-8501-DB13E96AFD08

P407

Q39118597-8E3B92D5-5718-4857-B854-AA93DA08C497

P433

Q39118597-2E839FE4-9367-4A32-89D9-A4D8FC102A0C

P478

Q39118597-748F6424-CAC8-46F0-B7D1-AB9A27E0708A

P50

Q39118597-595C60F0-98A1-40FC-BC3F-8C689C88AB71

Q39118597-A3D7531B-E5DC-4B81-A823-2C7BBFE9750D

Q39118597-E49670C0-92B4-4787-A239-C972A1843C92

P577

Q39118597-96DE30A2-2E3C-4033-A49E-BDB9C2919125

P5875

Q39118597-37E45FA9-95ED-4CAF-8741-5DE189A40448

P698

Q39118597-809DAFCF-E61E-4E2E-935F-9D00010AE8A9

P921

Q39118597-AE92C02F-26A1-42CF-B0E3-247307C5E11A

P932

Q39118597-D17A9C50-84DB-435A-88E3-243C0F68A361

P356

ONCOTARGET.1141

P1433

P1476

Combination therapy with anti- ...... its non-small cell lung cancer

@en

P2093

Alessia Noto

http://www.w3.org/2001/XMLSchema#string

Antonio D'Andrilli

http://www.w3.org/2001/XMLSchema#string

Debora Malpicci

http://www.w3.org/2001/XMLSchema#string

Emanuele Marra

http://www.w3.org/2001/XMLSchema#string

Giuseppe Roscilli

http://www.w3.org/2001/XMLSchema#string

Laura Luberto

http://www.w3.org/2001/XMLSchema#string

Luigi Aurisicchio

http://www.w3.org/2001/XMLSchema#string

Luigi Fattore

http://www.w3.org/2001/XMLSchema#string

Luigi Ruco

http://www.w3.org/2001/XMLSchema#string

Maria Rosaria Giovagnoli

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Roles of caveolin-1 on anoikis resistance in non small cell lung cancer

Spheres derived from lung adenocarcinoma pleural effusions: molecular characterization and tumor engraftment

P304

1253-1265

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.1141

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Gennaro Ciliberto

Pierpaolo Coluccia

Claudia De Vitis

P577

2013-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

253338636

http://www.w3.org/2001/XMLSchema#string

P698

23896512

http://www.w3.org/2001/XMLSchema#string

P921

P932

3787155

http://www.w3.org/2001/XMLSchema#string